Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2010

View Archived Issues

Eisai reports third quarter 2009 results

Prolor reports topline results from phase I study of CTP-modified human growth hormone

ChemoCentryx initiates phase I clinical trial of CCX-168 for autoimmune diseases

FDA approves Beech Tree's IND for phase I/IIa clinical trial of influenza drug BTL-TML-001

In vivo antiatherosclerotic effects of liver-selective thyromimetic support its clinical evaluation

Figitumumab safe and effective in phase I trial in adrenocortical carcinoma patients

Good safety profile of ciclosporin seen in severe traumatic brain injury patients

Conatus initiates phase II trial of CTS-1027 in combination with Pegasys and Copegus in HCV

Vertex reports preliminary results from phase IIa clinical trial of VX-809 in cystic fibrosis

GlaxoSmithKline discloses new agents for treating Flaviviridae virus infections

Faes Farma discloses novel anti-inflammatory compounds

Swissmedic approves BTG's DigiFab for life-threatening digitalis intoxication

Allergan presents new prostanoid EP2 receptor agonists

FDA accepts for filing Teva's BLA for XM-02 in neutropenia

Nano-sized conjugates with antiangiogenic activity disclosed by Ramot

Novel HDAC inhibitors identified by Karus Therapeutics

Isogenica and Phylogica sign partnership agreement for CIS display and Phylomer peptides

Apeiron and GSK sign agreement for enzyme biotherapeutic APN-01 for ARDS

Compugen discovers CGEN-15001 for treatment of autoimmune disorders

Stem Cell Therapy International and Histostem complete merger

ACT and University of Louisville sign agreement for identification of cancer drug candidates

United Therapeutics and Mondobiotech enter into global strategic partnership for aviptadil

Tanezumab relieves pain in three chronic conditions

Tapentadol IR and ER can be converted to equivalent daily doses

FDA approves Keryx's SPA for phase III X-PECT trial of perifosine in colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...